Branded

WHIPPANY, N.J. — Bayer on Tuesday announced that it had named Carsten Brunn as president of its pharmaceuticals division in the Americas. Brunn will oversee the company’s pharmaceutical arm in the United States, Canada, Central and Latin America, reporting to pharmaceutical division president and board of management member Dieter Weinand. 

 

GREENVILLE, N.C. — Mayne Pharma on Wednesday announced the launch of Fabior (tazarotene, 0.1%) Foam and Sorilux (calcipotiene, 0.005%) Foam. Mayne Pharma acquired the products from GSK in August 2016, and they complement the company’s Doryx, the first branded product in its specialty brands division that it launched in 2015. 

 

WILMINGTON, Del. — AstraZeneca on Monday announced the availability of its Bevespi Aerosphere (glycopyrrolate and formoterol fumarate) inhalation aerosol in the United States. The drug is indicated for long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease, including chronic bronchitis or emphysema. 

 

SILVER SPRING, Md. — The Food and Drug Administration has approved Arymo ER (morphine sulfate), an extended-release morphine tablet with abuse-deterrent properties, the company announced Monday. 

 

WASHINGTON — The Pharmaceutical Research and Manufacturers of America have announced Monday that Joaquin Duato, Johnson & Johnson’s worldwide chairman, pharmaceuticals, would be succeeding George Scangos, the outgoing CEO of Biogen, as the organization’s board chairman. 

 

WILMINGTON, Del. — U.S. District Court Judge Sue Robinson on Thursday issued an injunction on the sale of Praluent, a PCSK9 inhibitor from Sanofi and Regeneron. Amgen, maker of another PCSK9 inhibitor Repatha, filed the request for the injunction in 2016 after a jury found its patent infringement claims against Sanofi and Regeneron valid. 

 

SILVER SPRING, Md. — The Food and Drug Administration’s Center for Drug Evaluation and Research’s number of new drug approvals came in low in 2016, according to the agency’s year-end review of the new therapies that passed regulatory muster. The number of drugs the FDA approved last year, 22, is less than half of the 45 approved in 2015 and lower than the average of the last 10 years of approvals, which is 29.